 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Nature
401:188-193
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
|
|
M.S.Finnin,
J.R.Donigian,
A.Cohen,
V.M.Richon,
R.A.Rifkind,
P.A.Marks,
R.Breslow,
N.P.Pavletich.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are
important in the regulation of gene expression. HDACs are involved in cell-cycle
progression and differentiation, and their deregulation is associated with
several cancers. HDAC inhibitors, such as trichostatin A (TSA) and
suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can
inhibit cell growth, induce terminal differentiation and prevent the formation
of tumours in mice models, and they are effective in the treatment of
promyelocytic leukemia. Here we describe the structure of the histone
deacetylase catalytic core, as revealed by the crystal structure of a homologue
from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2%
identity with human HDAC1 over 375 residues, deacetylates histones in vitro and
is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and
deacetylase-SAHA structures reveal an active site consisting of a tubular
pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish
the mechanism of HDAC inhibition. The residues that make up the active site and
contact the inhibitors are conserved across the HDAC family. These structures
also suggest a mechanism for the deacetylation reaction and provide a framework
for the further development of HDAC inhibitors as antitumour agents.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3 TSA binds inside the pocket making contacts to
residues at the rim, walls and bottom of the pocket. a,
Space-filling representation of TSA in the active-site pocket.
The hydroxamic acid group, most of the aliphatic chain and part
of the dimethylamino-phenyl group of TSA are buried (60% of
TSA's surface area). The internal cavity has a volume of 144 ?3.
b, Closeup stereo view of the structure of the HDLP-Zn2+-TSA
complex in an orientation similar to Fig. 2a except for a 90°
rotation about the vertical axis. TSA is in white; active-site
residues and residues that contact TSA, which are all identical
in HDAC1 except Tyr 91, are in yellow. c, Schematic
representation of HDLP-TSA interactions. TSA is in black and the
protein is in red. HDLP residues are labelled in red with their
counterparts in HDAC1 indicated in black. Thatched semi-circles
indicate van der Waals contacts between hydrophobic protein
residues and TSA. Hydrogen bonds are shown as green dashed
lines. d, Surface representation of the HDLP-TSA interface in a
similar orientation to b. The protein surface is coloured
according to residue identity with HDAC1. Cyan indicates
residues that are identical in HDAC1.
|
 |
Figure 4.
Figure 4 SAHA binds HDLP like TSA, but its aliphatic chain
and cap groups make fewer contacts. Close-up view of the
HDLP-Zn2+-SAHA complex in the same orientation and colour scheme
as Fig. 3b. Note that Tyr 91 is not in the TSA-bound
conformation.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Macmillan Publishers Ltd:
Nature
(1999,
401,
188-193)
copyright 1999.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
A.Spannhoff,
Y.K.Kim,
N.J.Raynal,
V.Gharibyan,
M.B.Su,
Y.Y.Zhou,
J.Li,
S.Castellano,
G.Sbardella,
J.P.Issa,
and
M.T.Bedford
(2011).
Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees.
|
| |
EMBO Rep, 12,
238-243.
|
 |
|
|
|
|
 |
D.M.Griffith,
B.Szőcs,
T.Keogh,
K.Y.Suponitsky,
E.Farkas,
P.Buglyó,
and
C.J.Marmion
(2011).
Suberoylanilide hydroxamic acid, a potent histone deacetylase inhibitor; its X-ray crystal structure and solid state and solution studies of its Zn(II), Ni(II), Cu(II) and Fe(III) complexes.
|
| |
J Inorg Biochem, 105,
763-769.
|
 |
|
|
|
|
 |
G.I.Aldana-Masangkay,
and
K.M.Sakamoto
(2011).
The role of HDAC6 in cancer.
|
| |
J Biomed Biotechnol, 2011,
875824.
|
 |
|
|
|
|
 |
G.Li,
H.Jiang,
M.Chang,
H.Xie,
and
L.Hu
(2011).
HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
|
| |
J Neurol Sci, 304,
1-8.
|
 |
|
|
|
|
 |
M.Ouaïssi,
U.Giger,
I.Sielezneff,
N.Pirrò,
B.Sastre,
and
A.Ouaissi
(2011).
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
|
| |
J Biomed Biotechnol, 2011,
315939.
|
 |
|
|
|
|
 |
M.Rouffet,
and
S.M.Cohen
(2011).
Emerging trends in metalloprotein inhibition.
|
| |
Dalton Trans, 40,
3445-3454.
|
 |
|
|
|
|
 |
W.Tang,
T.Luo,
E.F.Greenberg,
J.E.Bradner,
and
S.L.Schreiber
(2011).
Discovery of histone deacetylase 8 selective inhibitors.
|
| |
Bioorg Med Chem Lett, 21,
2601-2605.
|
 |
|
|
|
|
 |
A.Hrzenjak,
F.Moinfar,
M.L.Kremser,
B.Strohmeier,
E.Petru,
K.Zatloukal,
and
H.Denk
(2010).
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
|
| |
Mol Cancer, 9,
49.
|
 |
|
|
|
|
 |
B.N.Singh,
G.Zhang,
Y.L.Hwa,
J.Li,
S.C.Dowdy,
and
S.W.Jiang
(2010).
Nonhistone protein acetylation as cancer therapy targets.
|
| |
Expert Rev Anticancer Ther, 10,
935-954.
|
 |
|
|
|
|
 |
B.Xiong,
S.Lu,
and
J.L.Gerton
(2010).
Hos1 is a lysine deacetylase for the Smc3 subunit of cohesin.
|
| |
Curr Biol, 20,
1660-1665.
|
 |
|
|
|
|
 |
G.Wu,
C.Nan,
J.C.Rollo,
X.Huang,
and
J.Tian
(2010).
Sodium valproate-induced congenital cardiac abnormalities in mice are associated with the inhibition of histone deacetylase.
|
| |
J Biomed Sci, 17,
16.
|
 |
|
|
|
|
 |
K.Kurosawa,
W.Lin,
and
K.Ohta
(2010).
Distinct roles of HDAC1 and HDAC2 in transcription and recombination at the immunoglobulin loci in the chicken B cell line DT40.
|
| |
J Biochem, 148,
201-207.
|
 |
|
|
|
|
 |
K.Sebova,
and
I.Fridrichova
(2010).
Epigenetic tools in potential anticancer therapy.
|
| |
Anticancer Drugs, 21,
565-577.
|
 |
|
|
|
|
 |
K.T.Smith,
S.A.Martin-Brown,
L.Florens,
M.P.Washburn,
and
J.L.Workman
(2010).
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
|
| |
Chem Biol, 17,
65-74.
|
 |
|
|
|
|
 |
K.W.Earley,
F.Pontvianne,
A.T.Wierzbicki,
T.Blevins,
S.Tucker,
P.Costa-Nunes,
O.Pontes,
and
C.S.Pikaard
(2010).
Mechanisms of HDA6-mediated rRNA gene silencing: suppression of intergenic Pol II transcription and differential effects on maintenance versus siRNA-directed cytosine methylation.
|
| |
Genes Dev, 24,
1119-1132.
|
 |
|
|
|
|
 |
L.Pan,
A.F.Matloob,
J.Du,
H.Pan,
Z.Dong,
J.Zhao,
Y.Feng,
Y.Zhong,
B.Huang,
and
J.Lu
(2010).
Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A /sodium butyrate-induced and 5-aza-2'-deoxycytidine-induced PTEN upregulation.
|
| |
FEBS J, 277,
989-999.
|
 |
|
|
|
|
 |
L.Yang,
J.Chen,
L.Shi,
M.P.Hudock,
K.Wang,
and
L.He
(2010).
Identifying unexpected therapeutic targets via chemical-protein interactome.
|
| |
PLoS One, 5,
e9568.
|
 |
|
|
|
|
 |
L.Zhang,
H.Fang,
and
W.Xu
(2010).
Strategies in developing promising histone deacetylase inhibitors.
|
| |
Med Res Rev, 30,
585-602.
|
 |
|
|
|
|
 |
M.G.Catalano,
R.Poli,
M.Pugliese,
N.Fortunati,
and
G.Boccuzzi
(2010).
Emerging molecular therapies of advanced thyroid cancer.
|
| |
Mol Aspects Med, 31,
215-226.
|
 |
|
|
|
|
 |
M.Godmann,
E.May,
and
S.Kimmins
(2010).
Epigenetic mechanisms regulate stem cell expressed genes Pou5f1 and Gfra1 in a male germ cell line.
|
| |
PLoS One, 5,
e12727.
|
 |
|
|
|
|
 |
N.Noureen,
H.Rashid,
and
S.Kalsoom
(2010).
Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
|
| |
Cancer Chemother Pharmacol, 66,
625-633.
|
 |
|
|
|
|
 |
N.Takai,
and
H.Narahara
(2010).
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
|
| |
Obstet Gynecol Int, 2010,
923824.
|
 |
|
|
|
|
 |
Q.P.Wang,
T.Kawahara,
and
D.Horn
(2010).
Histone deacetylases play distinct roles in telomeric VSG expression site silencing in African trypanosomes.
|
| |
Mol Microbiol, 77,
1237-1245.
|
 |
|
|
|
|
 |
R.Heinke,
and
W.Sippl
(2010).
[In Process Citation]
|
| |
Pharm Unserer Zeit, 39,
183-189.
|
 |
|
|
|
|
 |
S.L.Gantt,
C.G.Joseph,
and
C.A.Fierke
(2010).
Activation and inhibition of histone deacetylase 8 by monovalent cations.
|
| |
J Biol Chem, 285,
6036-6043.
|
 |
|
|
|
|
 |
T.Pirali,
V.Faccio,
R.Mossetti,
A.A.Grolla,
S.Di Micco,
G.Bifulco,
A.A.Genazzani,
and
G.C.Tron
(2010).
Synthesis, molecular docking and biological evaluation as HDAC inhibitors of cyclopeptide mimetics by a tandem three-component reaction and intramolecular [3+2] cycloaddition.
|
| |
Mol Divers, 14,
109-121.
|
 |
|
|
|
|
 |
W.J.Huang,
C.C.Chen,
S.W.Chao,
S.S.Lee,
F.L.Hsu,
Y.L.Lu,
M.F.Hung,
and
C.I.Chang
(2010).
Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
|
| |
ChemMedChem, 5,
598-607.
|
 |
|
|
|
|
 |
Y.K.Shi,
Z.H.Li,
X.Q.Han,
J.H.Yi,
Z.H.Wang,
J.L.Hou,
C.R.Feng,
Q.H.Fang,
H.H.Wang,
P.F.Zhang,
F.S.Wang,
J.Shen,
and
P.Wang
(2010).
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
|
| |
Cancer Chemother Pharmacol, 66,
1131-1140.
|
 |
|
|
|
|
 |
A.Bougdour,
D.Maubon,
P.Baldacci,
P.Ortet,
O.Bastien,
A.Bouillon,
J.C.Barale,
H.Pelloux,
R.Ménard,
and
M.A.Hakimi
(2009).
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites.
|
| |
J Exp Med, 206,
953-966.
|
 |
|
|
|
|
 |
A.K.Oyelere,
P.C.Chen,
W.Guerrant,
S.C.Mwakwari,
R.Hood,
Y.Zhang,
and
Y.Fan
(2009).
Non-peptide macrocyclic histone deacetylase inhibitors.
|
| |
J Med Chem, 52,
456-468.
|
 |
|
|
|
|
 |
A.Mai,
and
L.Altucci
(2009).
Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
|
| |
Int J Biochem Cell Biol, 41,
199-213.
|
 |
|
|
|
|
 |
A.Mai,
S.Valente,
A.Nebbioso,
S.Simeoni,
R.Ragno,
S.Massa,
G.Brosch,
F.De Bellis,
F.Manzo,
and
L.Altucci
(2009).
New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
|
| |
Int J Biochem Cell Biol, 41,
235-247.
|
 |
|
|
|
|
 |
A.Montero,
J.M.Beierle,
C.A.Olsen,
and
M.R.Ghadiri
(2009).
Design, Synthesis, Biological Evaluation, and Structural Characterization of Potent Histone Deacetylase Inhibitors Based on Cyclic alpha/beta-Tetrapeptide Architectures.
|
| |
J Am Chem Soc, 131,
3033-3041.
|
 |
|
|
|
|
 |
A.Mukai,
H.Komaki,
M.Takagi,
and
K.Shin-ya
(2009).
Novel siderophore, JBIR-16, isolated from Nocardia tenerifensis NBRC 101015.
|
| |
J Antibiot (Tokyo), 62,
601-603.
|
 |
|
|
|
|
 |
A.P.Kozikowski,
Y.Chen,
T.Subhasish,
N.E.Lewin,
P.M.Blumberg,
Z.Zhong,
M.A.D'Annibale,
W.L.Wang,
Y.Shen,
and
B.Langley
(2009).
Searching for disease modifiers-PKC activation and HDAC inhibition - a dual drug approach to Alzheimer's disease that decreases Abeta production while blocking oxidative stress.
|
| |
ChemMedChem, 4,
1095-1105.
|
 |
|
|
|
|
 |
A.Zubia,
S.Ropero,
D.Otaegui,
E.Ballestar,
M.F.Fraga,
M.Boix-Chornet,
M.Berdasco,
A.Martinez,
L.Coll-Mulet,
J.Gil,
F.P.Cossío,
and
M.Esteller
(2009).
Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
|
| |
Oncogene, 28,
1477-1484.
|
 |
|
|
|
|
 |
B.Song,
Y.Wang,
Y.Xi,
K.Kudo,
S.Bruheim,
G.I.Botchkina,
E.Gavin,
Y.Wan,
A.Formentini,
M.Kornmann,
O.Fodstad,
and
J.Ju
(2009).
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.
|
| |
Oncogene, 28,
4065-4074.
|
 |
|
|
|
|
 |
C.A.Olsen,
and
M.R.Ghadiri
(2009).
Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.
|
| |
J Med Chem, 52,
7836-7846.
|
 |
|
|
|
|
 |
D.Wang
(2009).
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.
|
| |
Curr Top Med Chem, 9,
241-256.
|
 |
|
|
|
|
 |
E.P.Jane,
D.R.Premkumar,
S.O.Addo-Yobo,
and
I.F.Pollack
(2009).
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
|
| |
J Pharmacol Exp Ther, 331,
327-337.
|
 |
|
|
|
|
 |
E.W.Schaefer,
A.Loaiza-Bonilla,
M.Juckett,
J.F.DiPersio,
V.Roy,
J.Slack,
W.Wu,
K.Laumann,
I.Espinoza-Delgado,
and
S.D.Gore
(2009).
A phase 2 study of vorinostat in acute myeloid leukemia.
|
| |
Haematologica, 94,
1375-1382.
|
 |
|
|
|
|
 |
F.Chen,
A.H.Gao,
J.Li,
and
F.J.Nan
(2009).
Synthesis and biological evaluation of c7-demethyl largazole analogues.
|
| |
ChemMedChem, 4,
1269-1272.
|
 |
|
|
|
|
 |
H.M.Wu,
N.S.Tzeng,
L.Qian,
S.J.Wei,
X.Hu,
S.H.Chen,
S.M.Rawls,
P.Flood,
J.S.Hong,
and
R.B.Lu
(2009).
Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation.
|
| |
Neuropsychopharmacology, 34,
2344-2357.
|
 |
|
|
|
|
 |
H.Nian,
B.Delage,
E.Ho,
and
R.H.Dashwood
(2009).
Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.
|
| |
Environ Mol Mutagen, 50,
213-221.
|
 |
|
|
|
|
 |
J.D.Sweatt
(2009).
Experience-dependent epigenetic modifications in the central nervous system.
|
| |
Biol Psychiatry, 65,
191-197.
|
 |
|
|
|
|
 |
J.Hu,
Y.Wang,
and
Y.Chen
(2009).
Curcumin-induced histone acetylation in malignant hematologic cells.
|
| |
J Huazhong Univ Sci Technolog Med Sci, 29,
25-28.
|
 |
|
|
|
|
 |
J.I.Lee,
H.Nian,
A.J.Cooper,
R.Sinha,
J.Dai,
W.H.Bisson,
R.H.Dashwood,
and
J.T.Pinto
(2009).
Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.
|
| |
Cancer Prev Res (Phila Pa), 2,
683-693.
|
 |
|
|
|
|
 |
J.L.MacDonald,
and
A.J.Roskams
(2009).
Epigenetic regulation of nervous system development by DNA methylation and histone deacetylation.
|
| |
Prog Neurobiol, 88,
170-183.
|
 |
|
|
|
|
 |
J.Long,
J.Zhao,
Z.Yan,
Z.Liu,
and
N.Wang
(2009).
Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
|
| |
Int J Cancer, 124,
1235-1244.
|
 |
|
|
|
|
 |
K.T.Smith,
and
J.L.Workman
(2009).
Histone deacetylase inhibitors: anticancer compounds.
|
| |
Int J Biochem Cell Biol, 41,
21-25.
|
 |
|
|
|
|
 |
L.Stimson,
V.Wood,
O.Khan,
S.Fotheringham,
and
N.B.La Thangue
(2009).
HDAC inhibitor-based therapies and haematological malignancy.
|
| |
Ann Oncol, 20,
1293-1302.
|
 |
|
|
|
|
 |
M.T.Epping,
and
R.Bernards
(2009).
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
|
| |
Int J Biochem Cell Biol, 41,
16-20.
|
 |
|
|
|
|
 |
N.C.Hait,
J.Allegood,
M.Maceyka,
G.M.Strub,
K.B.Harikumar,
S.K.Singh,
C.Luo,
R.Marmorstein,
T.Kordula,
S.Milstien,
and
S.Spiegel
(2009).
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate.
|
| |
Science, 325,
1254-1257.
|
 |
|
|
|
|
 |
N.Saban,
and
M.Bujak
(2009).
Hydroxyurea and hydroxamic acid derivatives as antitumor drugs.
|
| |
Cancer Chemother Pharmacol, 64,
213-221.
|
 |
|
|
|
|
 |
P.A.Marks,
and
W.S.Xu
(2009).
Histone deacetylase inhibitors: Potential in cancer therapy.
|
| |
J Cell Biochem, 107,
600-608.
|
 |
|
|
|
|
 |
P.H.Lee,
K.L.Kuo,
P.Y.Chu,
E.M.Liu,
and
J.H.Lin
(2009).
SLITHER: a web server for generating contiguous conformations of substrate molecules entering into deep active sites of proteins or migrating through channels in membrane transporters.
|
| |
Nucleic Acids Res, 37,
W559-W564.
|
 |
|
|
|
|
 |
R.Codd,
N.Braich,
J.Liu,
C.Z.Soe,
and
A.A.Pakchung
(2009).
Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
|
| |
Int J Biochem Cell Biol, 41,
736-739.
|
 |
|
|
|
|
 |
R.L.van Montfort,
and
P.Workman
(2009).
Structure-based design of molecular cancer therapeutics.
|
| |
Trends Biotechnol, 27,
315-328.
|
 |
|
|
|
|
 |
S.Cang,
Y.Ma,
and
D.Liu
(2009).
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
|
| |
J Hematol Oncol, 2,
22.
|
 |
|
|
|
|
 |
S.Schäfer,
L.Saunders,
S.Schlimme,
V.Valkov,
J.M.Wagner,
F.Kratz,
W.Sippl,
E.Verdin,
and
M.Jung
(2009).
Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors.
|
| |
ChemMedChem, 4,
283-290.
|
 |
|
|
|
|
 |
T.L.Newkirk,
A.A.Bowers,
and
R.M.Williams
(2009).
Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors.
|
| |
Nat Prod Rep, 26,
1293-1320.
|
 |
|
|
|
|
 |
T.Suzuki
(2009).
Explorative study on isoform-selective histone deacetylase inhibitors.
|
| |
Chem Pharm Bull (Tokyo), 57,
897-906.
|
 |
|
|
|
|
 |
V.Patel,
R.Mazitschek,
B.Coleman,
C.Nguyen,
S.Urgaonkar,
J.Cortese,
R.H.Barker,
E.Greenberg,
W.Tang,
J.E.Bradner,
S.L.Schreiber,
M.T.Duraisingh,
D.F.Wirth,
and
J.Clardy
(2009).
Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
|
| |
J Med Chem, 52,
2185-2187.
|
 |
|
|
|
|
 |
Y.Luo,
W.Jian,
D.Stavreva,
X.Fu,
G.Hager,
J.Bungert,
S.Huang,
and
Y.Qiu
(2009).
Trans-regulation of histone deacetylase activities through acetylation.
|
| |
J Biol Chem, 284,
34901-34910.
|
 |
|
|
|
|
 |
Y.Samuni,
W.Flores-Santana,
M.C.Krishna,
J.B.Mitchell,
and
D.A.Wink
(2009).
The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation.
|
| |
Free Radic Biol Med, 47,
419-423.
|
 |
|
|
|
|
 |
Y.T.Yang,
C.Balch,
S.K.Kulp,
M.R.Mand,
K.P.Nephew,
and
C.S.Chen
(2009).
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
|
| |
Neoplasia, 11,
552.
|
 |
|
|
|
|
 |
A.Hrzenjak,
M.L.Kremser,
B.Strohmeier,
F.Moinfar,
K.Zatloukal,
and
H.Denk
(2008).
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
|
| |
J Pathol, 216,
495-504.
|
 |
|
|
|
|
 |
A.I.Anzellotti,
and
N.P.Farrell
(2008).
Zinc metalloproteins as medicinal targets.
|
| |
Chem Soc Rev, 37,
1629-1651.
|
 |
|
|
|
|
 |
A.J.Vegas,
J.H.Fuller,
and
A.N.Koehler
(2008).
Small-molecule microarrays as tools in ligand discovery.
|
| |
Chem Soc Rev, 37,
1385-1394.
|
 |
|
|
|
|
 |
A.P.Kozikowski,
Y.Chen,
A.M.Gaysin,
D.N.Savoy,
D.D.Billadeau,
and
K.H.Kim
(2008).
Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors-nanomolar-potency inhibitors of pancreatic cancer cell growth.
|
| |
ChemMedChem, 3,
487-501.
|
 |
|
|
|
|
 |
A.Risch,
and
C.Plass
(2008).
Lung cancer epigenetics and genetics.
|
| |
Int J Cancer, 123,
1-7.
|
 |
|
|
|
|
 |
A.Schuetz,
J.Min,
A.Allali-Hassani,
M.Schapira,
M.Shuen,
P.Loppnau,
R.Mazitschek,
N.P.Kwiatkowski,
T.A.Lewis,
R.L.Maglathin,
T.H.McLean,
A.Bochkarev,
A.N.Plotnikov,
M.Vedadi,
and
C.H.Arrowsmith
(2008).
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.
|
| |
J Biol Chem, 283,
11355-11363.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Tong,
H.Zhang,
Z.Li,
L.Gou,
Z.Wang,
H.Wei,
M.Tang,
S.Liang,
L.Chen,
C.Huang,
and
Y.Wei
(2008).
Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
|
| |
Cancer Chemother Pharmacol, 61,
791-802.
|
 |
|
|
|
|
 |
A.V.Bieliauskas,
and
M.K.Pflum
(2008).
Isoform-selective histone deacetylase inhibitors.
|
| |
Chem Soc Rev, 37,
1402-1413.
|
 |
|
|
|
|
 |
B.Langley,
M.A.D'Annibale,
K.Suh,
I.Ayoub,
A.Tolhurst,
B.Bastan,
L.Yang,
B.Ko,
M.Fisher,
S.Cho,
M.F.Beal,
and
R.R.Ratan
(2008).
Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.
|
| |
J Neurosci, 28,
163-176.
|
 |
|
|
|
|
 |
C.C.Cortez,
and
P.A.Jones
(2008).
Chromatin, cancer and drug therapies.
|
| |
Mutat Res, 647,
44-51.
|
 |
|
|
|
|
 |
C.Haumaitre,
O.Lenoir,
and
R.Scharfmann
(2008).
Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors.
|
| |
Mol Cell Biol, 28,
6373-6383.
|
 |
|
|
|
|
 |
C.M.Lerche,
P.A.Philipsen,
M.Sehested,
and
H.C.Wulf
(2008).
Photocarcinogenesis of topical tazarotene and isotretinoin alone and in combination with valproic acid in hairless mice.
|
| |
Exp Dermatol, 17,
972-974.
|
 |
|
|
|
|
 |
C.M.Reilly,
M.Thomas,
R.Gogal,
S.Olgun,
A.Santo,
R.Sodhi,
E.T.Samy,
S.L.Peng,
G.S.Gilkeson,
and
N.Mishra
(2008).
The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice.
|
| |
J Autoimmun, 31,
123-130.
|
 |
|
|
|
|
 |
C.Ptak,
and
A.Petronis
(2008).
Epigenetics and complex disease: from etiology to new therapeutics.
|
| |
Annu Rev Pharmacol Toxicol, 48,
257-276.
|
 |
|
|
|
|
 |
C.T.Campbell,
U.Aich,
C.A.Weier,
J.J.Wang,
S.S.Choi,
M.M.Wen,
K.Maisel,
S.G.Sampathkumar,
and
K.J.Yarema
(2008).
Targeting pro-invasive oncogenes with short chain fatty acid-hexosamine analogues inhibits the mobility of metastatic MDA-MB-231 breast cancer cells.
|
| |
J Med Chem, 51,
8135-8147.
|
 |
|
|
|
|
 |
C.Yan,
Z.Xiu,
X.Li,
S.Li,
C.Hao,
and
H.Teng
(2008).
Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
|
| |
Proteins, 73,
134-149.
|
 |
|
|
|
|
 |
D.P.Dowling,
L.Di Costanzo,
H.A.Gennadios,
and
D.W.Christianson
(2008).
Evolution of the arginase fold and functional diversity.
|
| |
Cell Mol Life Sci, 65,
2039-2055.
|
 |
|
|
|
|
 |
D.P.Dowling,
S.L.Gantt,
S.G.Gattis,
C.A.Fierke,
and
D.W.Christianson
(2008).
Structural studies of human histone deacetylase 8 and its site-specific variants complexed with substrate and inhibitors.
|
| |
Biochemistry, 47,
13554-13563.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.W.Humphrey,
Y.H.Wang,
T.Hirai,
R.Padmanabhan,
D.M.Panchision,
L.F.Newell,
R.D.McKay,
and
B.H.Howard
(2008).
Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent stem cells.
|
| |
Differentiation, 76,
348-356.
|
 |
|
|
|
|
 |
H.Kobayashi,
N.Morisaki,
H.Miyachi,
and
Y.Hashimoto
(2008).
Coordination of divalent metal cation to amide group to form adduct ion in FAB mass spectrometry: implication of Zn2+ in enzymatic hydrolysis of amide bond.
|
| |
Chem Pharm Bull (Tokyo), 56,
672-676.
|
 |
|
|
|
|
 |
H.Zhang,
M.H.Muders,
J.Li,
F.Rinaldo,
D.J.Tindall,
and
K.Datta
(2008).
Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer.
|
| |
Cancer Res, 68,
8770-8778.
|
 |
|
|
|
|
 |
K.Strebhardt,
A.Ullrich,
and
P.Ehrlich
(2008).
Paul Ehrlich's magic bullet concept: 100 years of progress.
|
| |
Nat Rev Cancer, 8,
473-480.
|
 |
|
|
|
|
 |
K.T.Andrews,
T.N.Tran,
A.J.Lucke,
P.Kahnberg,
G.T.Le,
G.M.Boyle,
D.L.Gardiner,
T.S.Skinner-Adams,
and
D.P.Fairlie
(2008).
Potent antimalarial activity of histone deacetylase inhibitor analogues.
|
| |
Antimicrob Agents Chemother, 52,
1454-1461.
|
 |
|
|
|
|
 |
L.Balakrishnan,
and
B.Milavetz
(2008).
HDAC inhibitors stimulate viral transcription by multiple mechanisms.
|
| |
Virol J, 5,
43.
|
 |
|
|
|
|
 |
M.A.Hamon,
and
P.Cossart
(2008).
Histone modifications and chromatin remodeling during bacterial infections.
|
| |
Cell Host Microbe, 4,
100-109.
|
 |
|
|
|
|
 |
M.J.Allen,
J.P.Boyce,
M.T.Trentalange,
D.L.Treiber,
B.Rasmussen,
B.Tillotson,
R.Davis,
and
P.Reddy
(2008).
Identification of novel small molecule enhancers of protein production by cultured mammalian cells.
|
| |
Biotechnol Bioeng, 100,
1193-1204.
|
 |
|
|
|
|
 |
M.J.Bottomley,
P.Lo Surdo,
P.Di Giovine,
A.Cirillo,
R.Scarpelli,
F.Ferrigno,
P.Jones,
P.Neddermann,
R.De Francesco,
C.Steinkühler,
P.Gallinari,
and
A.Carfí
(2008).
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain.
|
| |
J Biol Chem, 283,
26694-26704.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Yoshida
(2008).
[Chemical biology of HDAC (histone deacetylase) inhibitors]
|
| |
Nippon Yakurigaku Zasshi, 132,
18-21.
|
 |
|
|
|
|
 |
N.B.Berry,
and
S.A.Bapat
(2008).
Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype.
|
| |
J Ovarian Res, 1,
8.
|
 |
|
|
|
|
 |
O.Binda,
C.Nassif,
and
P.E.Branton
(2008).
SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins.
|
| |
Oncogene, 27,
3384-3392.
|
 |
|
|
|
|
 |
O.Khan,
and
N.B.La Thangue
(2008).
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
|
| |
Nat Clin Pract Oncol, 5,
714-726.
|
 |
|
|
|
|
 |
P.A.Cole
(2008).
Chemical probes for histone-modifying enzymes.
|
| |
Nat Chem Biol, 4,
590-597.
|
 |
|
|
|
|
 |
S.V.Weerasinghe,
G.Estiu,
O.Wiest,
and
M.K.Pflum
(2008).
Residues in the 11 A channel of histone deacetylase 1 promote catalytic activity: implications for designing isoform-selective histone deacetylase inhibitors.
|
| |
J Med Chem, 51,
5542-5551.
|
 |
|
|
|
|
 |
X.J.Yang,
and
E.Seto
(2008).
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.
|
| |
Nat Rev Mol Cell Biol, 9,
206-218.
|
 |
|
|
|
|
 |
A.Lahm,
C.Paolini,
M.Pallaoro,
M.C.Nardi,
P.Jones,
P.Neddermann,
S.Sambucini,
M.J.Bottomley,
P.Lo Surdo,
A.Carfí,
U.Koch,
R.De Francesco,
C.Steinkühler,
and
P.Gallinari
(2007).
Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.
|
| |
Proc Natl Acad Sci U S A, 104,
17335-17340.
|
 |
|
|
|
|
 |
A.Mai
(2007).
The therapeutic uses of chromatin-modifying agents.
|
| |
Expert Opin Ther Targets, 11,
835-851.
|
 |
|
|
|
|
 |
A.Olasz,
K.Vanommeslaeghe,
A.Krishtal,
T.Veszprémi,
C.Van Alsenoy,
and
P.Geerlings
(2007).
The use of atomic intrinsic polarizabilities in the evaluation of the dispersion energy.
|
| |
J Chem Phys, 127,
224105.
|
 |
|
|
|
|
 |
A.Sekhavat,
J.M.Sun,
and
J.R.Davie
(2007).
Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
|
| |
Biochem Cell Biol, 85,
751-758.
|
 |
|
|
|
|
 |
A.V.Bieliauskas,
S.V.Weerasinghe,
and
M.K.Pflum
(2007).
Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
|
| |
Bioorg Med Chem Lett, 17,
2216-2219.
|
 |
|
|
|
|
 |
A.Vannini,
C.Volpari,
P.Gallinari,
P.Jones,
M.Mattu,
A.Carfí,
R.De Francesco,
C.Steinkühler,
and
S.Di Marco
(2007).
Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex.
|
| |
EMBO Rep, 8,
879-884.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
B.J.North,
and
E.Verdin
(2007).
Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis.
|
| |
PLoS ONE, 2,
e784.
|
 |
|
|
|
|
 |
C.Hildmann,
D.Riester,
and
A.Schwienhorst
(2007).
Histone deacetylases--an important class of cellular regulators with a variety of functions.
|
| |
Appl Microbiol Biotechnol, 75,
487-497.
|
 |
|
|
|
|
 |
C.M.Salisbury,
and
B.F.Cravatt
(2007).
Activity-based probes for proteomic profiling of histone deacetylase complexes.
|
| |
Proc Natl Acad Sci U S A, 104,
1171-1176.
|
 |
|
|
|
|
 |
C.Monneret
(2007).
Histone deacetylase inhibitors for epigenetic therapy of cancer.
|
| |
Anticancer Drugs, 18,
363-370.
|
 |
|
|
|
|
 |
F.E.Jacobsen,
J.A.Lewis,
and
S.M.Cohen
(2007).
The Design of Inhibitors for Medicinally Relevant Metalloproteins.
|
| |
ChemMedChem, 2,
152-171.
|
 |
|
|
|
|
 |
J.A.Marwick,
K.Ito,
I.M.Adcock,
and
P.A.Kirkham
(2007).
Oxidative stress and steroid resistance in asthma and COPD: pharmacological manipulation of HDAC-2 as a therapeutic strategy.
|
| |
Expert Opin Ther Targets, 11,
745-755.
|
 |
|
|
|
|
 |
J.J.Westendorf
(2007).
Histone deacetylases in control of skeletogenesis.
|
| |
J Cell Biochem, 102,
332-340.
|
 |
|
|
|
|
 |
J.M.Mehnert,
and
W.K.Kelly
(2007).
Histone deacetylase inhibitors: biology and mechanism of action.
|
| |
Cancer J, 13,
23-29.
|
 |
|
|
|
|
 |
J.R.Mays,
J.A.Restituyo,
R.J.Katzenberger,
D.A.Wassarman,
and
S.R.Rajski
(2007).
Cyclic Disulfides as Functional Mimics of the Histone Deacetylase Inhibitor FK-228.
|
| |
Tetrahedron Lett, 48,
4579-4583.
|
 |
|
|
|
|
 |
K.Kato,
M.Miyaji-Yamaguchi,
M.Okuwaki,
and
K.Nagata
(2007).
Histone acetylation-independent transcription stimulation by a histone chaperone.
|
| |
Nucleic Acids Res, 35,
705-715.
|
 |
|
|
|
|
 |
L.C.Huber,
J.H.Distler,
F.Moritz,
H.Hemmatazad,
T.Hauser,
B.A.Michel,
R.E.Gay,
M.Matucci-Cerinic,
S.Gay,
O.Distler,
and
A.Jüngel
(2007).
Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis.
|
| |
Arthritis Rheum, 56,
2755-2764.
|
 |
|
|
|
|
 |
L.Di Costanzo,
M.Moulin,
M.Haertlein,
F.Meilleur,
and
D.W.Christianson
(2007).
Expression, purification, assay, and crystal structure of perdeuterated human arginase I.
|
| |
Arch Biochem Biophys, 465,
82-89.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.Gomez-Paloma,
I.Bruno,
E.Cini,
S.Khochbin,
M.Rodriquez,
M.Taddei,
S.Terracciano,
and
K.Sadoul
(2007).
Design and Synthesis of Cyclopeptide Analogues of the Potent Histone Deacetylase Inhibitor FR235222.
|
| |
ChemMedChem, 2,
1511-1519.
|
 |
|
|
|
|
 |
L.Larsen,
M.Tonnesen,
S.G.Ronn,
J.Størling,
S.Jørgensen,
P.Mascagni,
C.A.Dinarello,
N.Billestrup,
and
T.Mandrup-Poulsen
(2007).
Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells.
|
| |
Diabetologia, 50,
779-789.
|
 |
|
|
|
|
 |
M.Martin,
R.Kettmann,
and
F.Dequiedt
(2007).
Class IIa histone deacetylases: regulating the regulators.
|
| |
Oncogene, 26,
5450-5467.
|
 |
|
|
|
|
 |
N.Aburai,
Y.Esumi,
H.Koshino,
N.Nishizawa,
and
K.Kimura
(2007).
Inhibitory activity of linoleic acid isolated from proso and Japanese millet toward histone deacetylase.
|
| |
Biosci Biotechnol Biochem, 71,
2061-2064.
|
 |
|
|
|
|
 |
P.A.Marks
(2007).
Discovery and development of SAHA as an anticancer agent.
|
| |
Oncogene, 26,
1351-1356.
|
 |
|
|
|
|
 |
P.A.Marks,
and
R.Breslow
(2007).
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.
|
| |
Nat Biotechnol, 25,
84-90.
|
 |
|
|
|
|
 |
P.Gallinari,
S.Di Marco,
P.Jones,
M.Pallaoro,
and
C.Steinkühler
(2007).
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
|
| |
Cell Res, 17,
195-211.
|
 |
|
|
|
|
 |
P.Kovács,
E.Pállinger,
and
G.Csaba
(2007).
Effect of histone deacetylase inhibitor trichostatin A (TSA) on the microtubular system of Tetrahymena.
|
| |
Acta Biol Hung, 58,
381-387.
|
 |
|
|
|
|
 |
R.Ikeda,
C.Kokubu,
K.Yusa,
V.W.Keng,
K.Horie,
and
J.Takeda
(2007).
Sleeping beauty transposase has an affinity for heterochromatin conformation.
|
| |
Mol Cell Biol, 27,
1665-1676.
|
 |
|
|
|
|
 |
R.L.Montgomery,
C.A.Davis,
M.J.Potthoff,
M.Haberland,
J.Fielitz,
X.Qi,
J.A.Hill,
J.A.Richardson,
and
E.N.Olson
(2007).
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
|
| |
Genes Dev, 21,
1790-1802.
|
 |
|
|
|
|
 |
S.C.Hodawadekar,
and
R.Marmorstein
(2007).
Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design.
|
| |
Oncogene, 26,
5528-5540.
|
 |
|
|
|
|
 |
S.Kern,
D.Riester,
C.Hildmann,
A.Schwienhorst,
and
F.J.Meyer-Almes
(2007).
Inhibitor-mediated stabilization of the conformational structure of a histone deacetylase-like amidohydrolase.
|
| |
FEBS J, 274,
3578-3588.
|
 |
|
|
|
|
 |
T.Hideshima,
and
K.C.Anderson
(2007).
Preclinical studies of novel targeted therapies.
|
| |
Hematol Oncol Clin North Am, 21,
1071.
|
 |
|
|
|
|
 |
T.K.Nielsen,
C.Hildmann,
D.Riester,
D.Wegener,
A.Schwienhorst,
and
R.Ficner
(2007).
Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun, 63,
270-273.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.M.Schroeder,
A.K.Nair,
R.Staggs,
A.F.Lamblin,
and
J.J.Westendorf
(2007).
Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors.
|
| |
BMC Genomics, 8,
362.
|
 |
|
|
|
|
 |
W.Aufsatz,
T.Stoiber,
B.Rakic,
and
K.Naumann
(2007).
Arabidopsis histone deacetylase 6: a green link to RNA silencing.
|
| |
Oncogene, 26,
5477-5488.
|
 |
|
|
|
|
 |
W.G.Nelson
(2007).
Prostate cancer prevention.
|
| |
Curr Opin Urol, 17,
157-167.
|
 |
|
|
|
|
 |
W.Renthal,
I.Maze,
V.Krishnan,
H.E.Covington,
G.Xiao,
A.Kumar,
S.J.Russo,
A.Graham,
N.Tsankova,
T.E.Kippin,
K.A.Kerstetter,
R.L.Neve,
S.J.Haggarty,
T.A.McKinsey,
R.Bassel-Duby,
E.N.Olson,
and
E.J.Nestler
(2007).
Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli.
|
| |
Neuron, 56,
517-529.
|
 |
|
|
|
|
 |
W.S.Xu,
R.B.Parmigiani,
and
P.A.Marks
(2007).
Histone deacetylase inhibitors: molecular mechanisms of action.
|
| |
Oncogene, 26,
5541-5552.
|
 |
|
|
|
|
 |
C.B.Yoo,
and
P.A.Jones
(2006).
Epigenetic therapy of cancer: past, present and future.
|
| |
Nat Rev Drug Discov, 5,
37-50.
|
 |
|
|
|
|
 |
C.Benjanirut,
M.Paris,
W.H.Wang,
S.J.Hong,
K.S.Kim,
R.L.Hullinger,
and
O.M.Andrisani
(2006).
The cAMP pathway in combination with BMP2 regulates Phox2a transcription via cAMP response element binding sites.
|
| |
J Biol Chem, 281,
2969-2981.
|
 |
|
|
|
|
 |
C.Sun,
X.Liu,
Y.Chen,
and
F.Liu
(2006).
Anticancer activities of trichostatin A on maligant lymphoid cells.
|
| |
J Huazhong Univ Sci Technolog Med Sci, 26,
538-541.
|
 |
|
|
|
|
 |
D.C.Juvale,
V.V.Kulkarni,
H.S.Deokar,
N.K.Wagh,
S.B.Padhye,
and
V.M.Kulkarni
(2006).
3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
|
| |
Org Biomol Chem, 4,
2858-2868.
|
 |
|
|
|
|
 |
G.Iacomino,
M.C.Medici,
D.Napoli,
and
G.L.Russo
(2006).
Effects of histone deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line.
|
| |
J Cell Biochem, 99,
1122-1131.
|
 |
|
|
|
|
 |
H.Uchida,
T.Maruyama,
T.Nagashima,
M.Ono,
H.Masuda,
T.Arase,
I.Sugiura,
M.Onouchi,
T.Kajitani,
H.Asada,
and
Y.Yoshimura
(2006).
Human endometrial cytodifferentiation by histone deacetylase inhibitors.
|
| |
Hum Cell, 19,
38-42.
|
 |
|
|
|
|
 |
H.Y.Lin,
C.S.Chen,
S.P.Lin,
J.R.Weng,
and
C.S.Chen
(2006).
Targeting histone deacetylase in cancer therapy.
|
| |
Med Res Rev, 26,
397-413.
|
 |
|
|
|
|
 |
I.Collins,
and
P.Workman
(2006).
New approaches to molecular cancer therapeutics.
|
| |
Nat Chem Biol, 2,
689-700.
|
 |
|
|
|
|
 |
J.Han,
L.Ding,
B.Yuan,
X.Yang,
X.Wang,
J.Li,
Q.Lu,
C.Huang,
and
Q.Ye
(2006).
Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells.
|
| |
Nucleic Acids Res, 34,
3095-3106.
|
 |
|
|
|
|
 |
K.W.Beekman,
and
M.Hussain
(2006).
Targeted approaches for the management of metastatic prostate cancer.
|
| |
Curr Oncol Rep, 8,
206-212.
|
 |
|
|
|
|
 |
L.Huang
(2006).
Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
|
| |
J Cell Physiol, 209,
611-616.
|
 |
|
|
|
|
 |
M.C.Myzak,
E.Ho,
and
R.H.Dashwood
(2006).
Dietary agents as histone deacetylase inhibitors.
|
| |
Mol Carcinog, 45,
443-446.
|
 |
|
|
|
|
 |
M.Hernandez,
Q.Shao,
X.J.Yang,
S.P.Luh,
M.Kandouz,
G.Batist,
D.W.Laird,
and
M.A.Alaoui-Jamali
(2006).
A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.
|
| |
Prostate, 66,
1151-1161.
|
 |
|
|
|
|
 |
M.Rodriquez,
S.Terracciano,
E.Cini,
G.Settembrini,
I.Bruno,
G.Bifulco,
M.Taddei,
and
L.Gomez-Paloma
(2006).
Total synthesis, NMR solution structure, and binding model of the potent histone deacetylase inhibitor FR235222.
|
| |
Angew Chem Int Ed Engl, 45,
423-427.
|
 |
|
|
|
|
 |
N.Kamath,
P.Karwowska-Desaulniers,
and
M.K.Pflum
(2006).
Limited proteolysis of human histone deacetylase 1.
|
| |
BMC Biochem, 7,
22.
|
 |
|
|
|
|
 |
N.R.White,
P.Mulligan,
P.J.King,
and
I.R.Sanderson
(2006).
Sodium butyrate-mediated Sp3 acetylation represses human insulin-like growth factor binding protein-3 expression in intestinal epithelial cells.
|
| |
J Pediatr Gastroenterol Nutr, 42,
134-141.
|
 |
|
|
|
|
 |
N.Sato,
N.Fukushima,
R.Chang,
H.Matsubayashi,
and
M.Goggins
(2006).
Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.
|
| |
Gastroenterology, 130,
548-565.
|
 |
|
|
|
|
 |
P.A.Konstantinopoulos,
G.P.Vandoros,
and
A.G.Papavassiliou
(2006).
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
|
| |
Cancer Chemother Pharmacol, 58,
711-715.
|
 |
|
|
|
|
 |
P.A.Marks
(2006).
Thioredoxin in cancer--role of histone deacetylase inhibitors.
|
| |
Semin Cancer Biol, 16,
436-443.
|
 |
|
|
|
|
 |
R.Butler,
and
G.P.Bates
(2006).
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
|
| |
Nat Rev Neurosci, 7,
784-796.
|
 |
|
|
|
|
 |
R.H.Dashwood,
M.C.Myzak,
and
E.Ho
(2006).
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?
|
| |
Carcinogenesis, 27,
344-349.
|
 |
|
|
|
|
 |
S.G.Sampathkumar,
M.B.Jones,
M.A.Meledeo,
C.T.Campbell,
S.S.Choi,
K.Hida,
P.Gomutputra,
A.Sheh,
T.Gilmartin,
S.R.Head,
and
K.J.Yarema
(2006).
Targeting glycosylation pathways and the cell cycle: sugar-dependent activity of butyrate-carbohydrate cancer prodrugs.
|
| |
Chem Biol, 13,
1265-1275.
|
 |
|
|
|
|
 |
S.Minucci,
and
P.G.Pelicci
(2006).
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
|
| |
Nat Rev Cancer, 6,
38-51.
|
 |
|
|
|
|
 |
T.C.Karagiannis,
and
A.El-Osta
(2006).
Modulation of cellular radiation responses by histone deacetylase inhibitors.
|
| |
Oncogene, 25,
3885-3893.
|
 |
|
|
|
|
 |
T.Huhtiniemi,
C.Wittekindt,
T.Laitinen,
J.Leppänen,
A.Salminen,
A.Poso,
and
M.Lahtela-Kakkonen
(2006).
Comparative and pharmacophore model for deacetylase SIRT1.
|
| |
J Comput Aided Mol Des, 20,
589-599.
|
 |
|
|
|
|
 |
V.Lakshmikanthan,
I.Kaddour-Djebbar,
R.W.Lewis,
and
M.V.Kumar
(2006).
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
|
| |
Int J Cancer, 119,
221-228.
|
 |
|
|
|
|
 |
W.Gu,
I.Nusinzon,
R.D.Smith,
C.M.Horvath,
and
R.B.Silverman
(2006).
Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
|
| |
Bioorg Med Chem, 14,
3320-3329.
|
 |
|
|
|
|
 |
Y.Nakao,
S.Yoshida,
S.Matsunaga,
N.Shindoh,
Y.Terada,
K.Nagai,
J.K.Yamashita,
A.Ganesan,
R.W.van Soest,
and
N.Fusetani
(2006).
Azumamides A-E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis.
|
| |
Angew Chem Int Ed Engl, 45,
7553-7557.
|
 |
|
|
|
|
 |
Y.Qiu,
Y.Zhao,
M.Becker,
S.John,
B.S.Parekh,
S.Huang,
A.Hendarwanto,
E.D.Martinez,
Y.Chen,
H.Lu,
N.L.Adkins,
D.A.Stavreva,
M.Wiench,
P.T.Georgel,
R.L.Schiltz,
and
G.L.Hager
(2006).
HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription.
|
| |
Mol Cell, 22,
669-679.
|
 |
|
|
|
|
 |
Ã.˜.Bruserud,
C.Stapnes,
K.J.Tronstad,
A.Ryningen,
N.Anensen,
and
B.T.Gjertsen
(2006).
Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.
|
| |
Expert Opin Ther Targets, 10,
51-68.
|
 |
|
|
|
|
 |
A.Mai,
S.Massa,
D.Rotili,
I.Cerbara,
S.Valente,
R.Pezzi,
S.Simeoni,
and
R.Ragno
(2005).
Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
|
| |
Med Res Rev, 25,
261-309.
|
 |
|
|
|
|
 |
B.F.Curtin,
L.M.Tetz,
J.R.Compton,
B.P.Doctor,
R.K.Gordon,
and
M.P.Nambiar
(2005).
Histone acetylase inhibitor trichostatin A induces acetylcholinesterase expression and protects against organophosphate exposure.
|
| |
J Cell Biochem, 96,
839-849.
|
 |
|
|
|
|
 |
D.C.Drummond,
C.O.Noble,
D.B.Kirpotin,
Z.Guo,
G.K.Scott,
and
C.C.Benz
(2005).
Clinical development of histone deacetylase inhibitors as anticancer agents.
|
| |
Annu Rev Pharmacol Toxicol, 45,
495-528.
|
 |
|
|
|
|
 |
F.Leoni,
G.Fossati,
E.C.Lewis,
J.K.Lee,
G.Porro,
P.Pagani,
D.Modena,
M.L.Moras,
P.Pozzi,
L.L.Reznikov,
B.Siegmund,
G.Fantuzzi,
C.A.Dinarello,
and
P.Mascagni
(2005).
The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo.
|
| |
Mol Med, 11,
1.
|
 |
|
|
|
|
 |
J.S.Ungerstedt,
Y.Sowa,
W.S.Xu,
Y.Shao,
M.Dokmanovic,
G.Perez,
L.Ngo,
A.Holmgren,
X.Jiang,
and
P.A.Marks
(2005).
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors.
|
| |
Proc Natl Acad Sci U S A, 102,
673-678.
|
 |
|
|
|
|
 |
K.Ekwall
(2005).
Genome-wide analysis of HDAC function.
|
| |
Trends Genet, 21,
608-615.
|
 |
|
|
|
|
 |
K.M.Gilbert,
S.R.Boger,
P.Price,
and
E.K.Fifer
(2005).
T cell tolerance induced by histone deacetylase inhibitor is mediated by P21cip1.
|
| |
Immunopharmacol Immunotoxicol, 27,
545-564.
|
 |
|
|
|
|
 |
K.Vanommeslaeghe,
F.De Proft,
S.Loverix,
D.Tourwé,
and
P.Geerlings
(2005).
Theoretical study revealing the functioning of a novel combination of catalytic motifs in histone deacetylase.
|
| |
Bioorg Med Chem, 13,
3987-3992.
|
 |
|
|
|
|
 |
M.Biel,
V.Wascholowski,
and
A.Giannis
(2005).
Epigenetics--an epicenter of gene regulation: histones and histone-modifying enzymes.
|
| |
Angew Chem Int Ed Engl, 44,
3186-3216.
|
 |
|
|
|
|
 |
M.Dokmanovic,
and
P.A.Marks
(2005).
Prospects: histone deacetylase inhibitors.
|
| |
J Cell Biochem, 96,
293-304.
|
 |
|
|
|
|
 |
M.Hernick,
H.A.Gennadios,
D.A.Whittington,
K.M.Rusche,
D.W.Christianson,
and
C.A.Fierke
(2005).
UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase functions through a general acid-base catalyst pair mechanism.
|
| |
J Biol Chem, 280,
16969-16978.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.K.Tripathi,
S.Misra,
S.V.Khedkar,
N.Hamilton,
C.Irvin-Wilson,
C.Sharan,
L.Sealy,
and
G.Chaudhuri
(2005).
Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells.
|
| |
J Biol Chem, 280,
17163-17171.
|
 |
|
|
|
|
 |
P.S.Espino,
B.Drobic,
K.L.Dunn,
and
J.R.Davie
(2005).
Histone modifications as a platform for cancer therapy.
|
| |
J Cell Biochem, 94,
1088-1102.
|
 |
|
|
|
|
 |
S.Ronzoni,
M.Faretta,
M.Ballarini,
P.Pelicci,
and
S.Minucci
(2005).
New method to detect histone acetylation levels by flow cytometry.
|
| |
Cytometry A, 66,
52-61.
|
 |
|
|
|
|
 |
S.Schäfer,
and
M.Jung
(2005).
Chromatin modifications as targets for new anticancer drugs.
|
| |
Arch Pharm (Weinheim), 338,
347-357.
|
 |
|
|
|
|
 |
T.Maeda,
Y.Nagaoka,
Y.Kawai,
N.Takagaki,
C.Yasuda,
S.Yogosawa,
Y.Sowa,
T.Sakai,
and
S.Uesato
(2005).
Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involve p21/WAF1 induction and G2/M arrest.
|
| |
Biol Pharm Bull, 28,
849-853.
|
 |
|
|
|
|
 |
W.K.Kelly,
and
P.A.Marks
(2005).
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
|
| |
Nat Clin Pract Oncol, 2,
150-157.
|
 |
|
|
|
|
 |
Y.Dai,
M.Rahmani,
P.Dent,
and
S.Grant
(2005).
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
|
| |
Mol Cell Biol, 25,
5429-5444.
|
 |
|
|
|
|
 |
Y.Guo,
J.Xiao,
Z.Guo,
F.Chu,
Y.Cheng,
and
S.Wu
(2005).
Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
|
| |
Bioorg Med Chem, 13,
5424-5434.
|
 |
|
|
|
|
 |
A.Vannini,
C.Volpari,
G.Filocamo,
E.C.Casavola,
M.Brunetti,
D.Renzoni,
P.Chakravarty,
C.Paolini,
R.De Francesco,
P.Gallinari,
C.Steinkühler,
and
S.Di Marco
(2004).
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
|
| |
Proc Natl Acad Sci U S A, 101,
15064-15069.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Villar-Garea,
and
M.Esteller
(2004).
Histone deacetylase inhibitors: understanding a new wave of anticancer agents.
|
| |
Int J Cancer, 112,
171-178.
|
 |
|
|
|
|
 |
B.J.North,
and
E.Verdin
(2004).
Sirtuins: Sir2-related NAD-dependent protein deacetylases.
|
| |
Genome Biol, 5,
224.
|
 |
|
|
|
|
 |
C.Hildmann,
M.Ninkovic,
R.Dietrich,
D.Wegener,
D.Riester,
T.Zimmermann,
O.M.Birch,
C.Bernegger,
P.Loidl,
and
A.Schwienhorst
(2004).
A new amidohydrolase from Bordetella or Alcaligenes strain FB188 with similarities to histone deacetylases.
|
| |
J Bacteriol, 186,
2328-2339.
|
 |
|
|
|
|
 |
C.S.Mitsiades,
N.S.Mitsiades,
C.J.McMullan,
V.Poulaki,
R.Shringarpure,
T.Hideshima,
M.Akiyama,
D.Chauhan,
N.Munshi,
X.Gu,
C.Bailey,
M.Joseph,
T.A.Libermann,
V.M.Richon,
P.A.Marks,
and
K.C.Anderson
(2004).
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
|
| |
Proc Natl Acad Sci U S A, 101,
540-545.
|
 |
|
|
|
|
 |
C.Y.Gui,
L.Ngo,
W.S.Xu,
V.M.Richon,
and
P.A.Marks
(2004).
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.
|
| |
Proc Natl Acad Sci U S A, 101,
1241-1246.
|
 |
|
|
|
|
 |
H.Lee,
N.Rezai-Zadeh,
and
E.Seto
(2004).
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A.
|
| |
Mol Cell Biol, 24,
765-773.
|
 |
|
|
|
|
 |
H.Park,
and
S.Lee
(2004).
Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors.
|
| |
J Comput Aided Mol Des, 18,
375-388.
|
 |
|
|
|
|
 |
H.S.Lee,
M.H.Park,
S.J.Yang,
H.Y.Jung,
S.S.Byun,
D.S.Lee,
H.S.Yoo,
Y.I.Yeom,
and
S.B.Seo
(2004).
Gene expression analysis in human gastric cancer cell line treated with trichostatin A and S-adenosyl-L-homocysteine using cDNA microarray.
|
| |
Biol Pharm Bull, 27,
1497-1503.
|
 |
|
|
|
|
 |
K.E.Joung,
D.K.Kim,
and
Y.Y.Sheen
(2004).
Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells.
|
| |
Arch Pharm Res, 27,
640-645.
|
 |
|
|
|
|
 |
K.N.Min,
M.J.Cho,
D.K.Kim,
and
Y.Y.Sheen
(2004).
Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells.
|
| |
Arch Pharm Res, 27,
554-561.
|
 |
|
|
|
|
 |
K.Nishida,
T.Komiyama,
S.Miyazawa,
Z.N.Shen,
T.Furumatsu,
H.Doi,
A.Yoshida,
J.Yamana,
M.Yamamura,
Y.Ninomiya,
H.Inoue,
and
H.Asahara
(2004).
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
|
| |
Arthritis Rheum, 50,
3365-3376.
|
 |
|
|
|
|
 |
L.Thevenet,
C.Méjean,
B.Moniot,
N.Bonneaud,
N.Galéotti,
G.Aldrian-Herrada,
F.Poulat,
P.Berta,
M.Benkirane,
and
B.Boizet-Bonhoure
(2004).
Regulation of human SRY subcellular distribution by its acetylation/deacetylation.
|
| |
EMBO J, 23,
3336-3345.
|
 |
|
|
|
|
 |
R.Kristeleit,
L.Stimson,
P.Workman,
and
W.Aherne
(2004).
Histone modification enzymes: novel targets for cancer drugs.
|
| |
Expert Opin Emerg Drugs, 9,
135-154.
|
 |
|
|
|
|
 |
S.Eyal,
B.Yagen,
E.Sobol,
Y.Altschuler,
M.Shmuel,
and
M.Bialer
(2004).
The activity of antiepileptic drugs as histone deacetylase inhibitors.
|
| |
Epilepsia, 45,
737-744.
|
 |
|
|
|
|
 |
S.M.Nelson,
L.R.Ferguson,
and
W.A.Denny
(2004).
DNA and the chromosome - varied targets for chemotherapy.
|
| |
Cell Chromosome, 3,
2.
|
 |
|
|
|
|
 |
V.Pennaneach,
V.Barbier,
K.Regazzoni,
R.Fotedar,
and
A.Fotedar
(2004).
Rb inhibits E2F-1-induced cell death in a LXCXE-dependent manner by active repression.
|
| |
J Biol Chem, 279,
23376-23383.
|
 |
|
|
|
|
 |
B.E.Coggins,
X.Li,
A.L.McClerren,
O.Hindsgaul,
C.R.Raetz,
and
P.Zhou
(2003).
Structure of the LpxC deacetylase with a bound substrate-analog inhibitor.
|
| |
Nat Struct Biol, 10,
645-651.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.L.Antos,
T.A.McKinsey,
M.Dreitz,
L.M.Hollingsworth,
C.L.Zhang,
K.Schreiber,
H.Rindt,
R.J.Gorczynski,
and
E.N.Olson
(2003).
Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors.
|
| |
J Biol Chem, 278,
28930-28937.
|
 |
|
|
|
|
 |
D.A.Whittington,
K.M.Rusche,
H.Shin,
C.A.Fierke,
and
D.W.Christianson
(2003).
Crystal structure of LpxC, a zinc-dependent deacetylase essential for endotoxin biosynthesis.
|
| |
Proc Natl Acad Sci U S A, 100,
8146-8150.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
F.McLaughlin,
P.Finn,
and
N.B.La Thangue
(2003).
The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age.
|
| |
Drug Discov Today, 8,
793-802.
|
 |
|
|
|
|
 |
H.Takigawa-Imamura,
T.Sekine,
M.Murata,
K.Takayama,
K.Nakazawa,
and
J.Nakagawa
(2003).
Stimulation of glucose uptake in muscle cells by prolonged treatment with scriptide, a histone deacetylase inhibitor.
|
| |
Biosci Biotechnol Biochem, 67,
1499-1506.
|
 |
|
|
|
|
 |
J.M.Denu
(2003).
Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent deacetylases.
|
| |
Trends Biochem Sci, 28,
41-48.
|
 |
|
|
|
|
 |
K.Zhao,
X.Chai,
A.Clements,
and
R.Marmorstein
(2003).
Structure and autoregulation of the yeast Hst2 homolog of Sir2.
|
| |
Nat Struct Biol, 10,
864-871.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Zhao,
X.Chai,
and
R.Marmorstein
(2003).
Structure of the yeast Hst2 protein deacetylase in ternary complex with 2'-O-acetyl ADP ribose and histone peptide.
|
| |
Structure, 11,
1403-1411.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.D.Jackson,
M.T.Schmidt,
N.J.Oppenheimer,
and
J.M.Denu
(2003).
Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases.
|
| |
J Biol Chem, 278,
50985-50998.
|
 |
|
|
|
|
 |
M.Verma,
B.K.Dunn,
S.Ross,
P.Jain,
W.Wang,
R.Hayes,
and
A.Umar
(2003).
Early detection and risk assessment: proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention.
|
| |
Ann N Y Acad Sci, 983,
298-319.
|
 |
|
|
|
|
 |
N.Klan,
S.Seuter,
N.Schnur,
M.Jung,
and
D.Steinhilber
(2003).
Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity.
|
| |
Biol Chem, 384,
777-785.
|
 |
|
|
|
|
 |
S.J.Haggarty,
K.M.Koeller,
J.C.Wong,
R.A.Butcher,
and
S.L.Schreiber
(2003).
Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays.
|
| |
Chem Biol, 10,
383-396.
|
 |
|
|
|
|
 |
S.Thiagalingam,
K.H.Cheng,
H.J.Lee,
N.Mineva,
A.Thiagalingam,
and
J.F.Ponte
(2003).
Histone deacetylases: unique players in shaping the epigenetic histone code.
|
| |
Ann N Y Acad Sci, 983,
84.
|
 |
|
|
|
|
 |
Y.Zhang,
N.Li,
C.Caron,
G.Matthias,
D.Hess,
S.Khochbin,
and
P.Matthias
(2003).
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo.
|
| |
EMBO J, 22,
1168-1179.
|
 |
|
|
|
|
 |
A.A.Ruefli,
D.Bernhard,
K.M.Tainton,
R.Kofler,
M.J.Smyth,
and
R.W.Johnstone
(2002).
Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells.
|
| |
Int J Cancer, 99,
292-298.
|
 |
|
|
|
|
 |
A.D.Weston,
R.A.Chandraratna,
J.Torchia,
and
T.M.Underhill
(2002).
Requirement for RAR-mediated gene repression in skeletal progenitor differentiation.
|
| |
J Cell Biol, 158,
39-51.
|
 |
|
|
|
|
 |
A.K.Ingram,
and
D.Horn
(2002).
Histone deacetylases in Trypanosoma brucei: two are essential and another is required for normal cell cycle progression.
|
| |
Mol Microbiol, 45,
89-97.
|
 |
|
|
|
|
 |
A.Melnick,
and
J.D.Licht
(2002).
Histone deacetylases as therapeutic targets in hematologic malignancies.
|
| |
Curr Opin Hematol, 9,
322-332.
|
 |
|
|
|
|
 |
A.N.Poux,
M.Cebrat,
C.M.Kim,
P.A.Cole,
and
R.Marmorstein
(2002).
Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor.
|
| |
Proc Natl Acad Sci U S A, 99,
14065-14070.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.R.Guardiola,
and
T.P.Yao
(2002).
Molecular cloning and characterization of a novel histone deacetylase HDAC10.
|
| |
J Biol Chem, 277,
3350-3356.
|
 |
|
|
|
|
 |
B.Schwer,
B.J.North,
R.A.Frye,
M.Ott,
and
E.Verdin
(2002).
The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase.
|
| |
J Cell Biol, 158,
647-657.
|
 |
|
|
|
|
 |
C.M.Grozinger,
and
S.L.Schreiber
(2002).
Deacetylase enzymes: biological functions and the use of small-molecule inhibitors.
|
| |
Chem Biol, 9,
3.
|
 |
|
|
|
|
 |
D.D.Fischer,
R.Cai,
U.Bhatia,
F.A.Asselbergs,
C.Song,
R.Terry,
N.Trogani,
R.Widmer,
P.Atadja,
and
D.Cohen
(2002).
Isolation and characterization of a novel class II histone deacetylase, HDAC10.
|
| |
J Biol Chem, 277,
6656-6666.
|
 |
|
|
|
|
 |
D.M.Vigushin,
and
R.C.Coombes
(2002).
Histone deacetylase inhibitors in cancer treatment.
|
| |
Anticancer Drugs, 13,
1.
|
 |
|
|
|
|
 |
F.Leoni,
A.Zaliani,
G.Bertolini,
G.Porro,
P.Pagani,
P.Pozzi,
G.Donà,
G.Fossati,
S.Sozzani,
T.Azam,
P.Bufler,
G.Fantuzzi,
I.Goncharov,
S.H.Kim,
B.J.Pomerantz,
L.L.Reznikov,
B.Siegmund,
C.A.Dinarello,
and
P.Mascagni
(2002).
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
|
| |
Proc Natl Acad Sci U S A, 99,
2995-3000.
|
 |
|
|
|
|
 |
G.He,
and
D.M.Margolis
(2002).
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat.
|
| |
Mol Cell Biol, 22,
2965-2973.
|
 |
|
|
|
|
 |
L.Gao,
M.A.Cueto,
F.Asselbergs,
and
P.Atadja
(2002).
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.
|
| |
J Biol Chem, 277,
25748-25755.
|
 |
|
|
|
|
 |
N.Adachi,
A.Kimura,
and
M.Horikoshi
(2002).
A conserved motif common to the histone acetyltransferase Esa1 and the histone deacetylase Rpd3.
|
| |
J Biol Chem, 277,
35688-35695.
|
 |
|
|
|
|
 |
P.Bjerling,
R.A.Silverstein,
G.Thon,
A.Caudy,
S.Grewal,
and
K.Ekwall
(2002).
Functional divergence between histone deacetylases in fission yeast by distinct cellular localization and in vivo specificity.
|
| |
Mol Cell Biol, 22,
2170-2181.
|
 |
|
|
|
|
 |
P.Dufourcq,
M.Victor,
F.Gay,
D.Calvo,
J.Hodgkin,
and
Y.Shi
(2002).
Functional requirement for histone deacetylase 1 in Caenorhabditis elegans gonadogenesis.
|
| |
Mol Cell Biol, 22,
3024-3034.
|
 |
|
|
|
|
 |
P.Gélébart,
T.Kovács,
J.P.Brouland,
R.van Gorp,
J.Grossmann,
N.Rivard,
Y.Panis,
V.Martin,
R.Bredoux,
J.Enouf,
and
B.Papp
(2002).
Expression of endomembrane calcium pumps in colon and gastric cancer cells. Induction of SERCA3 expression during differentiation.
|
| |
J Biol Chem, 277,
26310-26320.
|
 |
|
|
|
|
 |
R.Brown,
and
G.Strathdee
(2002).
Epigenomics and epigenetic therapy of cancer.
|
| |
Trends Mol Med, 8,
S43-S48.
|
 |
|
|
|
|
 | |